Use of Saccharomyces boulardii in Fermented Dairy Products

Year 2014, Volume: 12 Issue: 2, 108 - 113, 01.06.2014

Bayram Ürkek Mustafa Şengül Tuba Erkaya

Abstract

Fermented dairy products have an important place among functional foods because of their health beneficial microorganisms. When Saccharomyces boulardii, a probiotic yeast that can be used for commercial purposes, is used with bio-yogurt microflora containing probiotic microorganisms, growth of probiotic microorganisms have been reported to be stimulated and to contribute to the survival of probiotic bacteria. S. boulardii, in contrast to bacterial species, is more resistant against antibiotics, pepsin and bile. In addition to these features, S. boulardii is a bio-agent which can exhibit therapeutic effect. It can be used against antibiotic-associated diarrhea, acute diarrhea, recurrent Clostridium difficile infection, rotavirus-associated diarrhea in babies, inflamed intestinal infection and lactose malabsorption prevention. Despite of the many therapeutic properties of S. boulardii, there is no fermented dairy product which contains S. boulardii. In this review, the use of S. boulardii as a bio therapeutic culture in fermented dairy products is presented and its therapeutic effects are reviewed

Keywords

Saccharomyces boulardii, Yeast, Fermented dairy products, Therapeutic

Saccharomyces boulardii’nin Fermente Süt Ürünlerinde Kullanımı

Abstract

İçerdikleri yararlı mikroorganizmalar sayesinde fermente süt ürünleri fonksiyonel gıdalar arasında önemli bir yere sahiptirler. Ticari amaçla kullanılabilen probiyotik bir maya olan Saccharomyces boulardii’nin probiyotik mikroorganizmalar içeren biyoyoğurt mikroflorası ile birlikte kullanıldığı zaman probiyotik mikroorganizmaların gelişmesini teşvik ettiği ve probiyotik bakterilerin canlılığını sürdürmesine katkıda bulunduğu belirtilmektedir. Ayrıca, S. boulardii diğer bakteri türlerinden farklı olarak antibiyotiklere karşı daha dirençli olup mide asidi ve safra salgısından da etkilenmezler. Bu özelliklerinin yanı sıra S. boulardii terapötik etkisi olan bir biyo ajandır. Terapötik olarak antibiyotik kaynaklı ishallerde, akut ishal, tekrarlayan Clostridium difficile enfeksiyonlarında, bebeklerde rotavirüsün neden olduğu ishallerde, iltihaplı bağırsak enfeksiyonlarında ve laktoz malabsorbsiyonunun engellenmesi gibi amaçlar için de kullanılmaktadır. S.boulardii’nin birçok terapötik özelliği olmasına rağmen S.boulardii içeren bir fermente süt ürünü bulunmamaktadır. Bu derlemede biyoterapötik olarak kullanılan S. boulardii’nin fermente süt ürünlerinde kullanımı ve terapötik etkileri hakkında bilgi verilerek ve fermente süt ürünlerinde kullanımına dikkat çekilmeye çalışılacaktır

Keywords

Saccharomyces boulardii, Maya, Fermente süt ürünü, Terapötik

References

• Jakobsen, M., Narvhus, J., 1996. Yeasts and their beneficial and negative effects on the quality of dairy products. Int. Dairy J. 6: 755–768.
• Sanders, M.E., 2003. Probiotics: Considerations for human health. Nutrition Reviews 61(1): 91-99.
• Fuller, R., 1989. Probiotics in man and animals. Journal of Applied Bacteriology 66(5): 365–378.
• Marteau, P., Seksik, P., Jian, R., 2002. Probiotics and intestinal health effects: A clinical perspective. British Journal of Nutrition 88(1): 51-57.
• Sağdıç, O., Küçüköner, E., Özçelik, S., 2004. Probiyotik ve prebiyotiklerin fonksiyonel özellikleri. Atatürk Üniv. Ziraat Fak. Derg. 35(3-4): 221-228.
• Ouwehand, A.C., Salminen, S., Isolauri, E., 2002. Probiotics: An overview of beneficial effects. Antonie van Leeuwenhoek 82: 279-289.
• Kopp-Holihan, L., 2001. therapeutic uses of probiotics: A review. Journal of The American Dietetic Association 101(2): 229-241.
• Tok, E., Aslım, B., 2007. Probiyotik olarak kullanılan bazı laktik asit bakterilerinin kolesterol asimilasyonu ve safra tuzları dekonjugasyonundaki rolleri. Türk Mikrobiyol. Cem. Derg. 31(1): 62-68.
• Kundakçı, A., Ergönül, B., 2006. Probiyotik Gıda nedir? Ne değildir? 9. Gıda Kongresi, 24-26 Mayıs, Bolu, Türkiye, 93-96.
• McFarland, L.V., Bernasconi, P., 1993. Saccharomyces boulardii: A review of innovative biotherapeutic agent. Microbial Ecology in Health and Disease 6: 157-171.
• Ertör, O., 2003. Saccharomyces boulardii: İnfeksiyöz ishal tedavisinde yeni bir seçenek mi? Klimik Dergisi 16(1): 3-7.
• Czerucka, D., Piche, T., Rampal, P., 2007. Review article: Yeast as probiotics- Saccharomyces boulardii. Aliment. Pharmacol. Ther. 26: 767-778.
• Buts, J.P., Keyser, N.D., 2006. Effects of Saccharomyces boulardii on intestinal mucosa. Dig. Dis. Sci. 51: 1485-1492.
• Wyder, M.T., 2001. Yeast in dairy products. FAM Swiss Federal Dairy Research Station 425: 1-21.
• Fleet, G.H., 1990. Yeast in dairy products - a review. J. Appl. Bacteriol. 68: 199-211.
• Ouwehand, A.C., Salminen, S.J., 1998. The health effects of cultured milk products with viable and non-viable bacteria. Int. Dairy J. 8: 749-750.
• Lourens-Hatting, A., Viljoen, B.C., 2001. Growth and survival of a probiotic yeast in dairy products. Food Research International 34: 791-796.
• Guslandi, M., Giollo, P., Testoni, P.A., 2003. A pilot trial of Saccharomyces boulardii in ulcerative colits. European Hepatology 15(6): 697-698. Gastroenterology &
• Elmer, G.W., McFarland, L.V., Surawicz, C.M., Danko, L., Greenberg, R.N., 1999. Behaviour of Saccharomyces boulardii in recurrent Clostridium difficile disease patients. Aliment. Pharmacol. Ther. 13: 1663-1668.
• Castex, F., Corthier, G., Jouvert, S., Elmer, G.W., Lucas, F., Bastide, M., 1990. Prevention of Clostridium pseudomembranous colits by Saccharomyces boulardii: A scanning electron microscopic and microbiological Microbiology 136: 1085-1089. experimental study. Journal of General
• Buts, J.P., Corthier, G., Delmee, M., 1993. Saccharomyces boulardii for Clostridium difficile- associated enteropaties in infants. J. Pediatr. Gastroenterol. Nutr. 16: 419-425.
• Castagliuolo, I., Riegler, M.F., Valenick, L., LaMont, J.T., Pothoulakis, C., 1999. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B human colonic mucosa. Infection and Immunity 67(1): 302-307.
• Qamar, A., Aboudola, S., Warny, M., Michetti, P., Pothoulakis, C., LaMont, J.T., Kelly, C.P., 2001. Saccharoyces imunoglobulin A immune response to Clostridium difficile toxin A in mice. Infection and Immunity 69(4): 2762-2765. stimulates intestinal
• Guslandi, M., Mezzi, G., Sorghi, M., Testoni, P.A., 2000. Saccharomyces boulardii in maintenance treatment of Crohn’s disease. Digestive Diseases and Sciences 45(7): 1462-1464.
• Mansour-Ghanaei, F., Dehbashi, N., Yazdanparast, K., Shafaghi, A., 2003. Efficacy of Saccharomyces boulardii with antibiotics in acute amoebiasis. World J. Gastroenterol. 9(8): 1832-1833.
• Girard, P., Pansart, Y., Lorette, I., Gillardin, J.M., 2003. Dose-response relationship and mechanism of action of Saccharomyces boulardii in castor oil- induced diarrhea in rats. Digestive Diseases and Sciences 48(4): 770-774.
• Gaon, D., Garcia, H., Winter, L., Rodriguez, N., Quintas, R., Gonzalez, S.N., Oliver, G., 2003. Effect of Lactibacillus strains and Saccharomyces boulardii on persistent diarrhea in children. Medicina 63: 293-298.
• Htwe, K., Yee, K.S., Tin, M., Vandenplas, Y., 2008. Effect of Saccharomyces boulardii in the treatment of acute watery diarrhea in Myanmar children: A randomized controlled study. Am. J. Trop. Med. Hyg. 78(2): 214-216.
• Billoo, A.G., Memon, M.A., Khaskheli, S.A., Murtaza, G., Iqbal, K., Shekhani, M.S., Siddiqi, A.Q., 2006. Role of a probiotic (Sacccharomyces boulardii) in management and prevention of diarrhoe. World J. Gastroenterol. 12(28): 4557- 4560.
• Kurugöl, Z., Koturoğlu, G., 2005. Effects of Saccharomyces boulardii in children with akut diarrhoea. Acta Paediatrica 94: 44-47.
• Villarruel, G., Rubio, D.M., Lopez, F., Cintioni, J., Gurevech, R., Romero, G., Vandenplas, Y., 2007. Saccharomyces boulardii in acute childhood diarrhoea: A randomized placebo-controlled study. Acta Oaediatrica 96: 538-541.
• Höchter, W., Chase, D., Hagenhoff, G., 1990. Saccharomyces boulardii in acute adult diarrhoea: Efficacy and tolerability of treatment. Münch Med. Wschr. 132(12): 188-192.
• Cetine-Sauri, G., Basto, G.S., 1994. Therapeutic evaluation of Saccharomyces boulardii in children with acute diarrhea. Annales de Pediatrie 41(6): 397-400.
• Surawicz, C.M., Elmer, G.M., Speelman, P., McFarland, L.V., Chinn, J., VanBelle, G., 1989. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: A prospective study. Gastroenterology 96: 981-988.
• Toothaker, R., Elmer, G.W., 1984. Prevention of clindamycin-induced mortality in hamster by Saccharomyces boulardii. Antimicrobial Agents and Chemotherapy 26(4): 552-556.
• McFarland, L.V., Surawicz, C.M., Greenberg, R.N., Elmer, G.W., Moyer, K.A., Melcher, S.A., Bowen, K.E., Cox, J.L., 1995. Prevention of β-lactam- associated diarrhea by Saccharomyces boulardii compared with placebo. Am. J. Gastroenterol 90(3): 439-448.
• Can, M., Beşirbellioglu, B.A., Avci, I.Y., Beker, C.M., Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: A prospective study. Med. Sci. Monit. 12(4): 19-22. Prophylactic
• Kotowska, M., Albrecht, P., Szajewska, H., 2005. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea in children: A randomized double-blind placebo-controlled trial. Aliment. Pharmacol. Ther. 21: 583-590.
• Bleichner, G., Blėhaut, H., Mentec, H., Moyse, D., 1997. Saccharomyces boulardii prevents diarrhea in critically ill tube-fed patients. Intensive Care Med. 23: 517-523.
• Costalos, C., Skouteri, V., Gounaris, A., Sevastiadou, S., Triandafilidou, A., Ekonomidou, C., Kontaxaki, F., Petrochilou, V., 2003. Enteral feeding of premature infants with Saccharomyces boulardii. Early Human Development 74: 89-96.
• Guillot, C.C., Bacallao, E.G., Dominguez, M.S.C., Garcia, M.F., Gutierrez, P.M., 1995. Effects of Saccharomyces boulardii in children with chronic diarrhea, especially cases due to giardiasis. Revista Mexicana de Puericultura y Pediatria 2(12): 44-52.
• Saint-Marc, T., Blehaut, H., Musial, C., Touraine, J.L., 1995. AIDS-related diarrhea: A doubled-blind trial of Saccharomyces boulardii. Actualites Therapeutiques 23-24: 735-741.
• Hurduc, V., Plesca, D., Dragomir, D., Sajin, M., Vandenplas, Y., 2009. A randomized, open trial evaluating the effect of Saccharomyces boulardii on the eradication rate of Helicobacter pylori infection in children. Acta Paediatrica 99: 127-131.
• Cindoruk, M., Erkan, G., Karakan, T., Dursun, A., Unal, S., 2007. Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti- Helicobacter pylori therapy: A prospective randomized placebo-controlled double-blind study. Journal Complication 12: 309-316.
• Gedek, B.R., 1999. Adherence of Escherichia coli serogroup 0 157 and the Salmonella typhimurium mutant DT 104 to the surface of Saccharomyces boulardii. Mycoses 42: 261-264.
• Dahan, S., Dalmasso, G., Imbert, V., Peyron, J.F., Rampal, P., Czerucka, D., 2003. Saccharomyces boulardii Escherichia coli-induced signaling pathways in T84 cells. Infection and Immunity 71(2): 766-773.
• Akil, I., Yilmaz, O., Kurutepe, S., Degerli, K., Kavukcu, S., 2006. Influence of oral intake of Saccharomyces boulardii on Escherichia coli in enteric flora. Pediatr. Nephrol. 21: 807-810.
• Herek, Ö., Kara, İ.G., Kaleli, İ., 2004. Effects of antibiotics and Saccharomyces boulardii on bacterial translocation in burn injury. Surg. Today 34: 256-260.
• Geyik, M.F., Aldemir, M., Hosoglu, S., Ayaz, C., Satılmıs, S., Büyükbayram, H., Kokoglu, O.F., 2006. The effects of Saccharomyces boulardii on bacterial translocation in rats with obstructive jaundice. Ann. R. Coll. Surg. Engl. 88: 178-180.
• Ranadheera, R.D.C.S., Baines, S.K., Adams, M.C., 2010. Importance of food in probiotic efficacy. Food Research International 43: 1-7.
• Erbaş, M., 2006. Yeni bir gıda grubu olarak fonksiyonel gıdalar. 9. Gıda Kongresi, 24-26 Mayıs, Bolu, Türkiye, 792-795.
• Gürsoy, O., Kınık, Ö., 2006. Peynir üretiminde probiyotik bakterilerin kullanımı: Probiyotik peynir. Pamukkale Üniversitesi Mühendislik Bilimleri Dergisi 12(1): 105-116.